Moteur de recherche d’entreprises européennes
Financement de l’UE (2 812 437 €) : Une feuille de route de prévention ciblée pour l’avenir de l’éducation Hor26/08/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Une feuille de route de prévention ciblée pour l’avenir de l’éducation
"""PROPHET - a PeRsOnalized Prevention roadmap for the future HEalThcare"" will develop a Strategic Research and Innovation Agenda (SRIA) for Personalized Prevention, in order to support the implementation of innovative, sustainable and effective personalized programmes to prevent common chronic diseases. Technological biomedical advances (including omics data and digital tools) make risk stratification at the individual level possible. However, development of Personalized Prevention approaches must be accompanied by healthcare system transition, including citizen engagement, healthcare professional education and addressing organisational, social and legal issues. PROPHET will be centred around stakeholder engagement and the SRIA co-creation process in relation to three main strands of activities: Mapping, Assessment, and Building. Firstly, we will summarize, evaluate and discuss with the relevant stakeholders the extent to which all these new technologies can synergise (Mapping). Secondly, we will design a holistic framework (the PROPHET Framework) that will include all the necessary aspects to appraise Personalized Prevention approaches and their adoption by Public Health Authorities (Assessment). Thirdly, we will support the introduction of Personalised Prevention Programmes by providing guidelines for their design, engaging with healthcare professionals (especially those working with policy makers), and increasing health literacy at the population level on the benefits of Personalized Prevention (Building). PROPHET will liaise with other key current and forthcoming initiatives at EU level, such as ICPerMed, European Partnership (EP) PerMed, the CSA Beyond 1 Million Genomes (B1MG), and the EP on Transforming Health and Care Systems. The consortium consists of 18 beneficiaries and 2 affiliated entities across 12 EU Countries, and a large number of stakeholders already engaged from different Target Groups."
| Foundation for Genomics & Population Health | ? |
| Allelica Srl | 35 500 € |
| ASS Cittadinanzattiva ApS | 86 875 € |
| Biobanks AND Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric) | 84 812 € |
| Consorcio Centro de Investigacion Biomedica en Red M.P | 263 460 € |
| DEBRECENI EGYETEM | 45 875 € |
| EUROPEAN MOLECULAR BIOLOGY LABORATORY | 124 625 € |
| EUROPEAN PUBLIC HEALTH Association | 80 975 € |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs | 0,00 € |
| Forum des Patients Europeens | 98 750 € |
| GAC | 284 025 € |
| HELSINGIN YLIOPISTO | 85 811 € |
| Instituto de Salud Carlos III | 0,00 € |
| Instituto Nacional de Saude DR. Ricardo Jorge | 173 125 € |
| Karolinska Institutet | 197 375 € |
| Katholieke Universiteit Leuven | 159 500 € |
| STICHTING AMSTERDAM UMC | 186 250 € |
| TARTU ULIKOOL | 155 000 € |
| TERVEYDEN JA HYVINVOINNIN LAITOS | 175 064 € |
| Universita Cattolica Del Sacro Cuore | 451 415 € |
| Universiteit Gent | 25 670 € |
| UNIVERSITEIT VAN AMSTERDAM | 98 330 € |
https://cordis.europa.eu/project/id/101057721
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Foundation for Genomics & Population Health, Cambridge, Royaume Uni.
